New Paradigms for AntiCancer Drugs

Where You Are:

SEPTEMBER/OCTOBER 1999

Signal Transducers and Activators of Transcription: Novel Targets for Anticancer Therapeutics
Tammy Bowman, PhD; Hua Yu, PhD; Saïd Sebti, PhD; William Dalton, PhD, MD; and Richard Jove, PhD

Review of Three New Agents That Target Angiogenesis, Matrix Metalloproteinases, and Cyclin-Dependent Kinases
Richard M. Lush, PhD, Michelle A. Rudek, BS, and William D. Figg, PharmD

Pharmacology of Chemotherapy in the Older Cancer Patient
Lodovico Balducci, MD, and Claudia Beghé, MD
Evaluation of Palliative Endpoints in Oncology Clinical Trials
Paul B. Jacobsen, PhD, and Michael A. Weitzner, MD

Guest Editorial: Pharmacologic Treatment of Cancer — New Developments
William Dalton, PhD, MD

Oncology Pharmacotherapy: Thalidomide in Oncology — The Peril and the Promise
Rod Quilitz, PharmD

Ten Best Readings on New Anticancer Drugs
William Dalton, PhD, MD

Pathology Update: Nucleic Acid Amplification Testing — The New Infectious Disease Testing Method for Donor Blood
Moyne Treat Kornman, MD, German Leparc, MD, and Kaaron Benson, MD

Presentation Highlights: Complications of Cancer
Gail Broder, Carlos J. Sandoval-Cros, MD, and Ann Berger, RN, MSN, MD

Special Report: Reel Oncology — How Hollywood Films Portray Cancer
Robert A. Clark, MD, MBA

Calendar of Events

In the Next Issue

Clinical Research Protocols for Selected New Anticancer Agents

CME Instructions

Pretest

Posttest (Expired)


  Back to the Cancer Journal Index

For comments mail to: ccjournal@moffitt.usf.edu


The artwork on the Index and on the Table of Contents of this issue of Cancer Control features selections of still-life paintings in oils on canvas. From the Galerie Joel Roy, Biot, 06410, France.

 
 
 
TOOLS:   Font Size small font resizer separator font resizer separator big font resizer
 |  Site Map  |  Privacy Policy  |  Terms and Conditions